IL1B T-31C and VEGFA C+936T SNPs may be used as prognostic markers of rheumatoid arthritis treatment inefficiency

摘要

Objectives: The aim of our study was to analyze the association between some SNPs and treatment of rheumatoid arthritis with biological drugs.Patients and methods: We studied 368 Russian patients with rheumatoid arthritis. All of them were treated in accordance with the standard recommendations. Fifty seven patient received biological disease-modifying antirheumatic drugs. Single nucleotide polymorphisms (TNFA C-863A, TNFA G-308A, TNFA G-238A, IL1B T-31С, IL4 С-590T, IL6 G-174C, IL10 A-1082G, IL10 С-592А, VEGFA C+936T, VEGFA C-2578A) were determined by restriction fragment length polymorphism analysis of PCR-amplified fragments (PCR-RFLP) or RT-PCR.Results: The IL1B T-31C and VEGFA C+936T SNPs were association with bDMARDs treatment. Homozygotes IL1B -31CC and VEGFА +936 CC were more frequently in bDMARDs group compare with patients without bDMARDs (28.1% vs 17.1%, p=0.044 and 80.4% vs 66.6%, p=0.041). Other polymorphisms didn’t demonstrate any significant differences.Conclusions: Our data suggest, that IL1B T-31C and VEGFA C+936T SNPs can be used as part of a comprehensive assessment of the prognosis of the treatment effectiveness.